Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioDiscovery Awarded National Institutes of Health SBIR Grant

Published: Thursday, July 10, 2014
Last Updated: Wednesday, July 09, 2014
Bookmark and Share
SBIR Phase I grant to improve the copy number variation data from TCGA.

BioDiscovery, Inc. has announced the award of a Small Business Innovation Research (SBIR) Phase I grant from the National Institute of Health to improve the copy number variation (CNV) data from The Cancer Genome Atlas (TCGA), and has selected Huntsman Cancer Institute (HCI) at the University of Utah to assist in developing and validating the new product.

The commercial release of the improved TCGA copy number and sequence variant data will let researchers make further discoveries into tumorigenesis and disease progression and provide a meaningful validation set for internal studies.

“Our techniques for analyzing CNVs from raw data is unique and has proven highly effective, being used and cited in hundreds of publications.” says Soheil Shams, Ph.D., BioDiscovery’s Chief Scientific Officer. “We are applying methods, algorithms, and best practices learned from our experiences in clinical pathology settings to TCGA data. It’s a painstaking process, but the result will be the highest-fidelity CNV data from TCGA, and will integrate with our analysis platform to let researches quickly access and interrogate this database.”

“Copy number aberrations have been established as important drivers of many types of cancer, and as distinct from tumor classes driven primarily by somatic mutations,” says Louis Culot, Vice President of Marketing and Business Development at BioDiscovery.

Culot continued, “The NIH has recognized this, along with BioDiscovery’s unique expertise in CNV data analysis in the issue of this award. We are pleased to begin this work and expect it to have significant impact on further understanding of cancer genetics."

Joshua Schiffman, M.D., medical director of the High Risk Pediatric Cancer Clinic at Huntsman Cancer Institute (HCI) and associate professor of pediatrics at the University of Utah will be the lead investigator on the HCI arm of the project.

“The TCGA project, funded by NIH, has amazing potential but has proven challenging to unlock due to the processing of CNV information and difficulty in data access and analysis,” says Schiffman. “At HCI, we will work with the BioDiscovery team to help test and validate their approach to improved interaction with TCGA data sets. Results from these efforts will further our understanding of many types of cancer and hopefully lead to improved clinical care for patients.”

As part of the SBIR grant, Schiffman will work with BioDiscovery to demonstrate the clinical utility and translational impact of the TCGA data.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

N-of-One and BioDiscovery Partner
Partnership equips laboratories and oncologists with a foundation for genomic data analysis through to therapeutic options.
Tuesday, March 25, 2014
BioDiscovery Initiates Software Donation Program to Benefit Pediatric Research
Company to donate up to $100,000 worth of software licenses per year to eligible scientists working in pediatric research.
Monday, January 07, 2013
BioDiscovery and AGRE Enter into a Co-Promotion Agreement
Agreement allows AGRE to provide copy number and allelic event data to its research users.
Wednesday, September 19, 2012
Cancer Centers Renew and Expand BioDiscovery’s Nexus Copy Number Software Licenses
BioDiscovery announces a number of license renewals and expansions of its Nexus Copy Number product at leading cancer research centers.
Wednesday, December 16, 2009
Fox Chase Cancer Center Adopts Nexus Copy Number and Nexus Expression
The center's Keystone Program in Blood Cell Development and Cancer gains a site license for two bioinformatics software programs from BioDiscovery.
Wednesday, February 11, 2009
BioDiscovery Granted its 7th U.S. Patent for Microarray Image Analysis
The patent covers the fundamental step of quantifying spots in microarray images.
Friday, January 27, 2006
United Bioinformatica Inc. to distribute BioDiscovery products to Canadian market

Thursday, April 17, 2003
BioDiscovery Inc. and Genops Bioinformatics Inc. Collaboration

Thursday, February 27, 2003
BioDiscovery and Azign Bioscience in silico Collaboration

Tuesday, October 29, 2002
BioDiscovery Distribution Agreement With Sigma-Genosys

Wednesday, July 24, 2002
BioDiscovery Inc. and Genops Bioinformatics Inc. Collaboration

Wednesday, February 27, 2002
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!